Demographic, social, and behavioral correlates of SARS-CoV-2 seropositivity in a representative, population-based study of Minnesota residents.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
02
2022
accepted:
13
12
2022
medline:
19
6
2023
pubmed:
15
6
2023
entrez:
15
6
2023
Statut:
epublish
Résumé
Monitoring COVID-19 infection risk in the general population is a public health priority. Few studies have measured seropositivity using representative, probability samples. The present study measured seropositivity in a representative population of Minnesota residents prior to vaccines and assess the characteristics, behaviors, and beliefs of the population at the outset of the pandemic and their association with subsequent infection. Participants in the Minnesota COVID-19 Antibody Study (MCAS) were recruited from residents of Minnesota who participated in the COVID-19 Household Impact Survey (CIS), a population-based survey that collected data on physical health, mental health, and economic security information between April 20 and June 8 of 2020. This was followed by collection of antibody test results between December 29, 2020 and February 26, 2021. Demographic, behavioral, and attitudinal exposures were assessed for association with the outcome of interest, SARS-CoV-2 seroprevalence, using univariate and multivariate logistic regression. Of the 907 potential participants from the CIS, 585 respondents then consented to participate in the antibody testing (64.4% consent rate). Of these, results from 537 test kits were included in the final analytic sample, and 51 participants (9.5%) were seropositive. The overall weighted seroprevalence was calculated to be 11.81% (95% CI, 7.30%-16.32%) at of the time of test collection. In adjusted multivariate logistic regression models, significant associations between seroprevalence and the following were observed; being from 23-64 and 65+ age groups were both associated with higher odds of COVID-19 seropositivity compared to the 18-22 age group (17.8 [1.2-260.1] and 24.7 [1.5-404.4] respectively). When compared to a less than $30k annual income reference group, all higher income groups had significantly lower odds of seropositivity. Reporting practicing a number of 10 (median reported value in sample) or more of 19 potential COVID-19 mitigation factors (e.g. handwashing and mask wearing) was associated with lower odds of seropositivity (0.4 [0.1-0.99]) Finally, the presence of at least one household member in the age range of 6 to 17 years old was associated with higher odds of seropositivity (8.3 [1.2-57.0]). The adjusted odds ratio of SARS-CoV-2 seroprevalence was significantly positively associated with increasing age and having household member(s) in the 6-17 year age group, while increasing income levels and a mitigation score at or above the median were shown to be significantly protective factors.
Sections du résumé
BACKGROUND
Monitoring COVID-19 infection risk in the general population is a public health priority. Few studies have measured seropositivity using representative, probability samples. The present study measured seropositivity in a representative population of Minnesota residents prior to vaccines and assess the characteristics, behaviors, and beliefs of the population at the outset of the pandemic and their association with subsequent infection.
METHODS
Participants in the Minnesota COVID-19 Antibody Study (MCAS) were recruited from residents of Minnesota who participated in the COVID-19 Household Impact Survey (CIS), a population-based survey that collected data on physical health, mental health, and economic security information between April 20 and June 8 of 2020. This was followed by collection of antibody test results between December 29, 2020 and February 26, 2021. Demographic, behavioral, and attitudinal exposures were assessed for association with the outcome of interest, SARS-CoV-2 seroprevalence, using univariate and multivariate logistic regression.
RESULTS
Of the 907 potential participants from the CIS, 585 respondents then consented to participate in the antibody testing (64.4% consent rate). Of these, results from 537 test kits were included in the final analytic sample, and 51 participants (9.5%) were seropositive. The overall weighted seroprevalence was calculated to be 11.81% (95% CI, 7.30%-16.32%) at of the time of test collection. In adjusted multivariate logistic regression models, significant associations between seroprevalence and the following were observed; being from 23-64 and 65+ age groups were both associated with higher odds of COVID-19 seropositivity compared to the 18-22 age group (17.8 [1.2-260.1] and 24.7 [1.5-404.4] respectively). When compared to a less than $30k annual income reference group, all higher income groups had significantly lower odds of seropositivity. Reporting practicing a number of 10 (median reported value in sample) or more of 19 potential COVID-19 mitigation factors (e.g. handwashing and mask wearing) was associated with lower odds of seropositivity (0.4 [0.1-0.99]) Finally, the presence of at least one household member in the age range of 6 to 17 years old was associated with higher odds of seropositivity (8.3 [1.2-57.0]).
CONCLUSIONS
The adjusted odds ratio of SARS-CoV-2 seroprevalence was significantly positively associated with increasing age and having household member(s) in the 6-17 year age group, while increasing income levels and a mitigation score at or above the median were shown to be significantly protective factors.
Identifiants
pubmed: 37319239
doi: 10.1371/journal.pone.0279660
pii: PONE-D-22-04448
pmc: PMC10270347
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0279660Informations de copyright
Copyright: © 2023 Abhold et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
No competing interests.
Références
Sci Immunol. 2020 Jul 29;5(49):
pubmed: 32727884
JAMA. 2020 Jun 16;323(23):2425-2427
pubmed: 32421144
medRxiv. 2020 Nov 13;:
pubmed: 33200150
mSphere. 2021 Feb 3;6(1):
pubmed: 33536325
Trop Med Health. 2021 Jul 10;49(1):55
pubmed: 34246317
Nat Commun. 2020 Sep 17;11(1):4698
pubmed: 32943630
JAMA Intern Med. 2021 Apr 1;181(4):450-460
pubmed: 33231628
Occup Environ Med. 2020 Dec;77(12):857-861
pubmed: 32764107
Am J Epidemiol. 2021 Jan 4;190(1):109-115
pubmed: 32803245
Emerg Infect Dis. 2021 Nov;27(1):
pubmed: 33171096
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1221-1226
pubmed: 32881855
Infect Control Hosp Epidemiol. 2022 May;43(5):657-660
pubmed: 33706827
Int J Equity Health. 2021 Nov 24;20(1):248
pubmed: 34819081
Emerg Infect Dis. 2020 Dec;26(12):2863-2871
pubmed: 32956614
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
Ethn Health. 2021 Jan;26(1):22-35
pubmed: 33334160
Ann Epidemiol. 2020 Aug;48:23-29.e4
pubmed: 32648546
Emerg Infect Dis. 2020 Nov;26(11):2766-2769
pubmed: 32731911
JAMA Netw Open. 2021 Feb 1;4(2):e2035234
pubmed: 33555331
Emerg Infect Dis. 2021 Feb;27(2):669-672
pubmed: 33496649
Front Cell Infect Microbiol. 2022 Sep 16;12:932563
pubmed: 36189360
Fisc Stud. 2020 Sep;41(3):709-732
pubmed: 33362315
Nat Commun. 2021 Jun 18;12(1):3737
pubmed: 34145289
PLoS One. 2021 Jun 23;16(6):e0252617
pubmed: 34161316
Nat Commun. 2020 Sep 1;11(1):4378
pubmed: 32873791
Math Biosci. 2021 Mar;333:108545
pubmed: 33460673
Int J Infect Dis. 2021 Jan;102:63-69
pubmed: 33075539